OBJECTIVES:  The aim of this study was to synthesize the evidence on cost-effectiveness of treatment for hyperphosphatemia in chronic kidney disease Patients. METHODS:  Using “hyperphosphatemia”,“ chronic kidney disease”, “cost” and “economic evaluation” as the keywords for searching in PUBMED. Among 70 articles, we selected eight related articles for review.. RESULTS:  First, researches in this area are more concentrated in developed countries, such as UK, Canada and US. Then, in most countries, they use Markov model based on on the clinical cohort. Two articles mentioned that Lanthanum carbonate is associated with considerable clinical benefits and good value for money in CKD（£6900/QALY gained, UK）. One paper point that Lanthanum carbonate is a cost-effective strategy compared with Sevelamer in the treatment of ESRD patients with hyperphosphatemia who were previously treated with calcium -based binders(for completer population was considered, the ICERs of LC versus sevelamer were $15,285/QALY and $9,337/LYS). There are five literature suggests, sevelamer is a cost-effective drug for the treatment of hyperphosphatemia in patients with CKD（2.70 QALYs,£25,916 /QALYs,UK ; 18 life-years, Canada） CONCLUSIONS: We get different results from the existing international studies which couldn’t inform desion makers in China. So, it’s necessary for us to carry out the research in the Chinese setting in the future.